¼¼°èÀÇ ÇåÆÃÅϺ´ Ä¡·á ½ÃÀå : ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ - ¾àÁ¦ À¯Çüº°, À¯Åë ä³Îº°, ¿¬·Éº°, Áö¿ªº° Àü¸Á°ú ¿¹Ãø(2024-2031³â)
Global Huntington¢¥s Disease Treatment Market Size, Share & Trends Analysis Report By Drug Type (Approved Drugs (Tetrabenazine and Deutetrabenazine) and Offlabel Drugs), By Distribution Channel, By Age, By Regional Outlook and Forecast, 2024 - 2031
»óǰÄÚµå : 1511393
¸®¼­Ä¡»ç : KBV Research
¹ßÇàÀÏ : 2024³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 266 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,600 £Ü 5,108,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,320 £Ü 6,130,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ 10¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,048 £Ü 8,582,000
PDF (Corporate User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ÇåÆÃÅÏ º´ Ä¡·á ½ÃÀå ±Ô¸ð´Â ¿¹Ãø ±â°£ µ¿¾È 9.0%ÀÇ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÏ¿© 2031³â±îÁö 8¾ï 510¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

±×·¯³ª HD¸¦ À¯¹ßÇÏ´Â HTT À¯ÀüÀÚÀÇ µ¹¿¬º¯ÀÌ´Â µ¶¼º µ¹¿¬º¯ÀÌ ÇåÆÃƾ ´Ü¹éÁú(mHTT)À» »ý¼ºÇÕ´Ï´Ù. ÀÌ À¯ÀüÀÚ º¯ÀÌ´Â ½Å°æ ±â´É Àå¾Ö¸¦ ÀÏÀ¸Å°°í °á±¹ ½Å°æ ÅðÇàÀ» ÀÏÀ¸ ŵ´Ï´Ù. ¶ÇÇÑ, HDÀÇ ÀÓ»ó Áõ»óÀº Áõ»óÀÇ ¹ßÇö°ú ÁøÇà ¸ðµÎ¿¡¼­ °³Àΰ£¿¡ Å©°Ô ´Ù¸¨´Ï´Ù. µû¶ó¼­ º¹ÀâÇÑ Áúº´ º´Å »ý¸®ÇÐÀº ½ÃÀå ¼ºÀåÀ» ¹æÇØÇÕ´Ï´Ù.

À¯ÇàÇÐÀº ·Ï´Ù¿î, ¿©Çà Á¦ÇÑ ¹× COVID - 19¸¦ ´Ù·ç´Â °Ç°­ °ü¸® ÀÚ¿øÀÇ Àç¹èÆ÷·Î ÀÎÇØ ÇåÆÃÅÏ º´ÀÇ ÀÓ»ó½ÃÇèÀÇ ´ëºÎºÐÀ» Áß´ÜÇϰųª ¿¬±âÇß½À´Ï´Ù. ¶ÇÇÑ, À¯Çà¿¡ ÀÇÇØ ¾ß±âµÈ ¼¼°è °ø±Þ¸ÁÀÇ È¥¶õÀº HD ȯÀÚ¸¦ À§ÇÑ ÀǾàǰ ¹× ÀÇ·á ¿ëǰÀÇ °¡¿ë¼º¿¡ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. µû¶ó¼­ COVID - 19 ÆÒµ¥¹ÍÀº ½ÃÀå¿¡ ºÎÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù.

¾àÁ¦ À¯Çüº° Àü¸ÁÀÔ´Ï´Ù.

ÇåÆÃÅÏ º´ Ä¡·á ½ÃÀåÀº ¾à¹°ÀÇ À¯Çü¿¡ µû¶ó ½ÂÀÎ ¾à¹°°ú ÀûÀÀ ¿Ü¾àÀ¸·Î ³ª´¹´Ï´Ù. 2023³â ÀûÀÀ ¿Ü¾à ºÎ¹®Àº ÇåÆÃÅÏ º´ Ä¡·á ½ÃÀå¿¡¼­ 15.3%ÀÇ ¼öÀÍ Á¡À¯À²À» ȹµæÇß½À´Ï´Ù. ÀûÀÀ ¿Ü¾àÀº Á¤½Å Áõ»ó(¿ì¿ïÁõ, ºÒ¾È µî), Àڱؼº, ÀÎÁö Àå¾Ö µî ÇåÆÃÅϺ´ÀÇ Æ¯Á¤ Áõ»óÀ» °ü¸®ÇÏ´Â µ¥ ÀáÀçÀûÀÎ ÀÌÁ¡À» Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù. °Ç°­ °ü¸® Á¦°ø¾÷ü´Â ȯÀÚÀÇ »îÀÇ Áú¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡´Â ÀÌ·¯ÇÑ ¾î·Á¿î Áõ»óÀ» ¿ÏÈ­Çϱâ À§ÇØ ÀûÀÀ ¿Ü ¿É¼ÇÀ» °í·ÁÇÒ ¼ö ÀÖ½À´Ï´Ù.

À¯Åë ä³Îº° Àü¸ÁÀÔ´Ï´Ù.

À¯Åë ä³ÎÀ» ±â¹ÝÀ¸·Î ÇåÆÃÅÏ º´ Ä¡·á ½ÃÀåÀº º´¿ø ¾à±¹, ¾à±¹ ¹× ¼Ò¸Å ¾à±¹, ¿Â¶óÀÎ ¾à±¹À¸·Î ºÐ·ùµË´Ï´Ù. 2023³â¿¡´Â ¾à±¹ ¹× ¼Ò¸Å ¾à±¹ ºÎ¹®ÀÌ ÇåÆÃÅÏ º´ Ä¡·á ½ÃÀå¿¡¼­ 32.7%ÀÇ ¼öÀÍ Á¡À¯À²À» ȹµæÇß½À´Ï´Ù. ¼Ò¸Å ¾à±¹¿¡¼­´Â ¹«µµº´(ºÒ¼öÀǿ), Á¤½ÅÁõ»ó(¿ì¿ïÁõ, ºÒ¾È µî), ÀÎÁöÀå¾Ö µîÀÇ Ä¡·áÁ¦À» Æ÷ÇÔÇÑ ÇåÆÃÅϺ´°ú °ü·ÃµÈ Áõ»óÀ» °ü¸®Çϴµ¥ »ç¿ëµÇ´Â ´Ù¾çÇÑ ¾àÀ» Àç°íÇϰí ÀÖ½À´Ï´Ù.

¿¬·Éº° Àü¸ÁÀÔ´Ï´Ù.

¿¬·Éº°·Î º¸¸é ÇåÆÃÅϺ´ Ä¡·á ½ÃÀåÀº 50¼¼ ¹Ì¸¸°ú 50¼¼ ÀÌ»óÀ¸·Î ³ª´µ¾îÁ® ÀÖ½À´Ï´Ù. 2023³â¿¡´Â 50¼¼ ÀÌ»óÀÇ ºÎ¹®ÀÌ ÇåÆÃÅÏ º´ Ä¡·á ½ÃÀåÀÇ ¼öÀÍ Á¡À¯À²ÀÇ 43.3%¸¦ Â÷ÁöÇß½À´Ï´Ù. ÇåÆÃÅÏ º´Àº ³ëÀε鿡°Ô ¹Ì¹¦ÇÑ Áõ»ó°ú ºñÁ¤»óÀûÀÎ Áõ»óÀ» ³ªÅ¸³¾ ¼ö ÀÖÀ¸¸ç Áø´Ü Áö¿¬À¸·Î À̾îÁú ¼ö ÀÖ½À´Ï´Ù. ÀÎÁöµµ¿Í Áø´Ü ´É·ÂÀÌ Çâ»óµÊ¿¡ µû¶ó 50¼¼ ÀÌ»óÀÇ »ç¶÷µéÀÌ HD·Î Áø´ÜµÇ°í Áõ»óÀ» ÇØ°áÇÏ°í »îÀÇ ÁúÀ» ÃÖÀûÈ­Çϱâ À§ÇÑ Ä¡·á ¹× °ü¸® Àü·«ÀÇ ½ÃÀÛÀÌ Ã˱¸µÉ ¼ö ÀÖÀ½ ÀÖ½À´Ï´Ù.

Áö¿ªº° Àü¸ÁÀÔ´Ï´Ù.

Áö¿ªº°·Î º¸¸é ÇåÆÃÅϺ´ Ä¡·á ½ÃÀåÀº ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿, ¾ÆÇÁ¸®Ä«¿¡ °ÉÃÄ ºÐ¼®µÇ°í ÀÖ½À´Ï´Ù. ºÏ¹Ì´Â 2023³â ÇåÆÃÅÏ º´ Ä¡·á ½ÃÀå¿¡¼­ 42%ÀÇ ¼öÀÍ Á¡À¯À²À» ±â·ÏÇß½À´Ï´Ù. ºÏ¹Ì´Â ´Ù¸¥ Áö¿ªº¸´Ù ÇåÆÃÅϺ´ÀÇ À¯º´·üÀÌ »ó´ëÀûÀ¸·Î ³ô½À´Ï´Ù. ÀÌ Áúº´Àº ºÏ¹ÌÀÇ¿¡¼­ ´«¿¡ ¶ç´Â À¯·´Àǰè Àα¸µé »çÀÌ¿¡¼­ ´õ ÀϹÝÀûÀ¸·Î Áø´ÜµË´Ï´Ù. ¶ÇÇÑÀÌ Áö¿ªÀº »ý¹° ÀÇÇÐ Á¶»ç ¹× ÀǾàǰ Çõ½ÅÀÇ ¼¼°èÀûÀÎ ¸®´õÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ½ÃÀå ¹üÀ§¿Í Á¶»ç ¹æ¹ý

Á¦2Àå ½ÃÀå ¿ä¶÷

Á¦3Àå ½ÃÀå °³¿ä

Á¦4Àå ÇåÆÃÅϺ´ Ä¡·á ½ÃÀå : ¾àÁ¦ À¯Çüº°

Á¦5Àå ÇåÆÃÅϺ´ Ä¡·á ½ÃÀå : À¯Åë ä³Îº°

Á¦6Àå ÇåÆÃÅϺ´ Ä¡·á ½ÃÀå : ¿¬·Éº°

Á¦7Àå ÇåÆÃÅϺ´ Ä¡·á ½ÃÀå : Áö¿ªº°

Á¦8Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦9Àå ÇåÆÃÅϺ´ Ä¡·á ½ÃÀåÀÇ ¼º°ø Çʼö Á¶°Ç

BJH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Global Huntington's Disease Treatment Market size is expected to reach $805.1 million by 2031, rising at a market growth of 9.0% CAGR during the forecast period.

The Asia-Pacific region's nations are investing in expanding and modernizing its hospitals, clinics, and specialized treatment facilities. Better facilities and access to healthcare enable HD patients to receive sophisticated treatment choices, interdisciplinary care, and early diagnosis. Consequently, the Asia pacific region would acquire nearly 25% of the total market share by 2031. Genetic diversity within the Asia Pacific region provides unique opportunities for studying Huntington's Disease genetics, disease variants, and population-specific factors influencing disease progression.

Huntington's disease is caused by a mutation in the HTT gene, which produces an abnormal form of the huntingtin protein. Moreover, RNA interference (RNAi) and antisense oligonucleotides (ASOs) are biotechnological approaches that can reduce the expression of the mutant HTT gene. Moreover, RNA interference (RNAi) and antisense oligonucleotides (ASOs) are biotechnological approaches that can reduce the expression of the mutant HTT gene. Additionally, Healthcare expenditure encompasses funding allocated to biomedical research, including neurodegenerative diseases like Huntington's disease. Furthermore, investments in healthcare infrastructure, such as specialized clinics, research centers, and laboratory facilities, are essential for advancing HD research and treatment. Therefore, rising healthcare expenditures and investments are propelling the market's growth.

However, A poisonous mutant huntingtin protein (mHTT) results from an HTT gene mutation that causes HD. This genetic mutation leads to neuronal dysfunction and eventual neurodegeneration. Moreover, the clinical manifestations of HD vary widely among individuals, both in terms of symptom onset and progression. Thus, complex disease pathophysiology is hampering the growth of the market.

The pandemic led to the suspension or delay of many clinical trials for Huntington's Disease due to lockdowns, travel restrictions, and the reallocation of healthcare resources to address COVID-19. In addition, the global supply chain disruptions caused by the pandemic affected the availability of medications and medical supplies for HD patients. Thus, the COVID-19 pandemic had a negative impact on the market.

Drug Type Outlook

Based on drug type, the Huntington's disease treatment market is divided into approved drugs and offlabel drugs. In 2023, the offlable drugs segment acquired 15.3% revenue share in the Huntington's disease treatment market. Off-label drugs may offer potential benefits in managing specific symptoms of Huntington's Disease, such as psychiatric symptoms (e.g., depression, anxiety), irritability, and cognitive impairment. Healthcare providers may explore off-label options to alleviate these challenging symptoms that significantly impact patient quality of life.

Distribution Channel Outlook

On the basis of distribution channel, the Huntington's disease treatment market is segmented into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. In 2023, the drug stores & retail pharmacies segment attained 32.7% revenue share in the Huntington's disease treatment market. Retail pharmacies stock a variety of medications used to manage symptoms associated with Huntington's Disease, including medications for chorea (involuntary movements), psychiatric symptoms (e.g., depression, anxiety), and cognitive impairments.

Age Outlook

By age, the Huntington's disease treatment market is bifurcated into below 50 years and above 50 years. The above 50 segment held 43.3% revenue share in the Huntington's disease treatment market in 2023. Huntington's Disease can present with subtle or atypical symptoms in older adults, leading to delays in diagnosis. As awareness and diagnostic capabilities improve, more individuals above 50 years old may receive a diagnosis of HD, prompting the initiation of treatment and management strategies to address symptoms and optimize quality of life.

Regional Outlook

Region-wise, the Huntington's disease treatment market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region witnessed 42% revenue share in the Huntington's disease treatment market in 2023. North America has a relatively higher Huntington's Disease prevalence than other regions. The disease is more commonly diagnosed among populations of European descent, which are prominent in North America. Also, the region is a global leader in biomedical research and pharmaceutical innovation.

List of Key Companies Profiled

Global Huntington's Disease Treatment Market Report Segmentation

By Drug Type

By Distribution Channel

By Age

By Geography

Table of Contents

Chapter 1. Market Scope & Methodology

Chapter 2. Market at a Glance

Chapter 3. Market Overview

Chapter 4. Global Huntington's Disease Treatment Market by Drug Type

Chapter 5. Global Huntington's Disease Treatment Market by Distribution Channel

Chapter 6. Global Huntington's Disease Treatment Market by Age

Chapter 7. Global Huntington's Disease Treatment Market by Region

Chapter 8. Company Profiles

Chapter 9. Winning Imperatives of Huntington's Disease Treatment Market

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â